Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group

eJHaem

article

Francesca Fazio¹  Luca Franceschini²  Valeria Tomarchio³  Angela Rago⁴  Maria Grazia Garzia⁵  Luca Cupelli⁶  Velia Bongarzoni⁷  Alessandro Andriani⁸  Svitlana Gumenyuk⁹  Agostino Tafuri^1,10  Agostina Siniscalchi^1,11  Alfonso Piciocchi^1,12  Paolo De Fabritiis^1,13  Luca De Rosa^1,14  Tommaso Caravita di Toritto^1,15  Ombretta Annibali^1,16  Maria Cantonetti^1,17  Maria Teresa Petrucci¹ 

[1]Department of Translational and Precision Medicine, Hematology, Azienda Policlinico Umberto I, Sapienza University of RomeSapienza Università di Roma

[2]Transplant Network

[3]Department of Haematology, University Campus Biomedico

[4]ASL RM/A

[5]Department of Hematology, Hematology, San Camillo Forlanini Hospital

[6]Department of Hematology, Hematology, Ospedale Sant'Eugenio

[7]Department of Hematology, San Giovanni-Addolorata Hospital

[8]Department of Hematology, Ospedale Fabrizio Spaziani

[9]Haematology and Stem Cell Transplant, Regina Elena National Cancer Institute

[10]Azienda Ospedaliera Sant'Andrea

[11]S. Eugenio Hospital, Institute of Haematology

[12]Data Center, Italian Group for Adult Hematologic Diseases

[13]Department of Haematology, Ospedale Sant'Eugenio

[14]Hematology and Bone Marrow Transplantation Unit, Azienda Ospedaliera San Camillo-Forlanini

[15]Department of Hematology

[16]Department of Haematology, Campus Bio-Medico University of Rome

[17]Chair of Hematology, Universita Tor Vergata

关键词: immunotherapy;    multiple myeloma;    relapsed refractory;   

DOI  :  10.1002/jha2.359

来源: Wiley

【 摘 要 】

The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD38 with tumor activity associated with immunomodulatory mechanism. In combination with standard of care regimens, including bortezomib (Vd) or lenalidomide (Rd), daratumumab prolonged progression-free survival (PFS) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and in new diagnosis MM. We report the data of the MM GIMEMA Lazio group in 171 heavily treated pts who received daratumumab, lenalidomide and dexamethasone (DRd) or daratumumab, velcade and dexamethasone (DVd). The overall response rate was 80%, and the overall survival (OS) and PFS were 84% and 77%, respectively. In addition, pts treated with DRd showed a better median PFS compared to pts treated with DVd, at 12 and 24 months, respectively. The most common hematologic treatment-emergent adverse events (TAEs) were neutropenia, thrombocytopenia, and anemia. The most common nonhematologic TAEs were peripheral sensory neuropathy and infections. Our data confirmed that DRd or DVd therapy is effective and safe in RRMM pts, and our real-life analysis could support the physicians regarding the choice of optimal therapy in this setting of pts.

【 授权许可】

Unknown